Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study-Reference-Cited by-同舟云学术

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

Published:2012-06 Issue:6 Volume:56 Page:1247-1253
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Moreno Christophe,Berg Thomas,Tanwandee Tawesak,Thongsawat Satawat,Van Vlierberghe Hans,Zeuzem Stefan,Lenz Oliver,Peeters Monika,Sekar Vanitha,De Smedt Goedele

Publisher

Elsevier BV

Subject

Hepatology

Reference40 articles.

1. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;Hepatology,2009

2. The global burden of hepatitis C;Lavanchy;Liver Int,2009

3. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes;Simmonds;Hepatology,2005

4. Genetic diversity and evolution of hepatitis C virus in the Latin American region;Cristina;J Clin Virol,2005

5. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994;Alter;N Engl J Med,1999

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study;Health Science Reports;2020-02-22

2. Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study;Cogent Medicine;2020-02-18

3. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study;Journal of Gastroenterology;2020-02-17

4. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy;Journal of Interferon & Cytokine Research;2019-09-01

5. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1;Hepatology;2019-03-14